Analysts Offer Predictions for Valneva SE's FY2024 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN - Free Report) - HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Valneva in a note issued to investors on Friday, October 11th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of $0.00 for the year, down from their prior forecast of $0.02. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Valneva's current full-year earnings is $0.02 per share.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.02. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. The business had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million.

Valneva Price Performance

NASDAQ VALN traded up $0.02 on Monday, reaching $5.65. The company had a trading volume of 4,392 shares, compared to its average volume of 10,858. The firm's 50 day moving average price is $6.77 and its 200 day moving average price is $7.44. Valneva has a 12 month low of $5.57 and a 12 month high of $14.49. The stock has a market capitalization of $393.45 million, a PE ratio of -13.76 and a beta of 2.17. The company has a quick ratio of 2.15, a current ratio of 2.63 and a debt-to-equity ratio of 0.97.

Hedge Funds Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC increased its holdings in Valneva SE (NASDAQ:VALN - Free Report) by 42.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,252 shares of the company's stock after purchasing an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned approximately 0.13% of Valneva worth $649,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.